Nghiên cứu giai đoạn I/II kiểm tra sự kết hợp của các hạt nano AGuIX với xạ hóa trị và temozolomide đồng thời ở bệnh nhân mới được chẩn đoán bị u nguyên bào thần kinh đệm (giai đoạn thí nghiệm NANO-GBM)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.
Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2010;97(3):377–81.
Kotb S, Detappe A, Lux F, Appaix F, Barbier EL, Tran VL, et al. Gadolinium-based nanoparticles and radiation therapy for multiple brain melanoma metastases: proof of concept before phase I trial. Theranostics. 2016;6(3):418–27.
Dufort S, Le Duc G, Salomé M, Bentivegna V, Sancey L, Bräuer-Krisch E, et al. The high radiosensitizing efficiency of a trace of gadolinium-based nanoparticles in tumors. Sci Rep. 2016;6:29678.
Bianchi A, Moncelet D, Lux F, Plissonneau M, Rizzitelli S, Ribot EJ, et al. Orotracheal administration of contrast agents: a new protocol for brain tumor targeting. NMR Biomed. 2015;28(6):738–46.
Dufort S, Bianchi A, Henry M, Lux F, Le Duc G, Josserand V, et al. Nebulized gadolinium-based nanoparticles: a theranostic approach for lung tumor imaging and radiosensitization. Small Weinh Bergstr Ger. 2015;11(2):215–21.
Verry C, Dufort S, Barbier EL, Montigon O, Peoc’h M, Chartier P, et al. MRI-guided clinical 6-MV radiosensitization of glioma using a unique gadolinium-based nanoparticles injection. Nanomed. 2016;11(18):2405–17.
Le Duc G, Miladi I, Alric C, Mowat P, Bräuer-Krisch E, Bouchet A, et al. Toward an image-guided microbeam radiation therapy using gadolinium-based nanoparticles. ACS Nano. 2011;5(12):9566–74.
Miladi I, Aloy MT, Armandy E, Mowat P, Kryza D, Magné N, et al. Combining ultrasmall gadolinium-based nanoparticles with photon irradiation overcomes radioresistance of head and neck squamous cell carcinoma. Nanomedicine Nanotechnol Biol Med. 2015;11(1):247–57.
Detappe A, Kunjachan S, Sancey L, Motto-Ros V, Biancur D, Drane P, et al. Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy. J Control Release Off J Control Release Soc. 2016;238:103–13.
Sancey L, Lux F, Kotb S, Roux S, Dufort S, Bianchi A, et al. The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. Br J Radiol. 2014;87(1041):20140134.
Dufort S, Appelboom G, Verry C, Barbier EL, Lux F, Bräuer-Krisch E, et al. Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival. J Clin Neurosci. 2019;67:215–9.
Verry C, Dufort S, Villa J, Gavard M, Iriart C, Grand S, et al. Theranostic AGuIX nanoparticles as radiosensitizer: a phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Radiother Oncol J Eur Soc Ther Radiol Oncol. 2021;160:159–65.
Verry C, Dufort S, Lemasson B, Grand S, Pietras J, Troprès I, et al. Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective. Sci Adv. 2020;6(29):eaay5279.
Cheung YK, Chappell R. Sequential designs for phase i clinical trials with late-onset toxicities. Biometrics. 2000;56(4):1177–82.